Skip to content
thestock.space

Themis Medicare (THEMISMED) had a P/E of 23.4× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 28% below their 52-week high. Its ROCE of 2.5% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit fell 0.4% and 73% a year over 3 years, though net profit is above operating profit, which points to a one-off gain. Its dividend yield is 0.5%, and debt is 0.25× equity. It is a small-cap company with a market cap of ₹940 Cr, ranked 73rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 17% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹101.64
Day high
₹102.88
Day low
₹99.48
Prev. close
₹101.64
Volume
56.9K

Health check

5 to check
  • ReturnsBehind

    −16.9% over a year, better than 0 of 7 peers.

  • Price tagDistorted

    A one-off gain inflates profit, so P/E isn’t comparable right now.

  • GrowthShrinking

    Sales −0.4%, profit −72.8% a year over 3 years.

  • ProfitabilityWeak

    ROCE 2.5% vs peer median 17.9%.

  • Balance sheetStretched

    Debt 0.25× equity, interest covered 1.2×, Piotroski 2 of 9.

  • Red flags4 to check

    Return on equity is low at 0.3%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹940 Cr, #73 of 154 in its industry by size.

Defensive

Beta 0.67 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹332 Cr · profit ₹40 Cr
Market cap
₹940 Cr
Small cap
P/E
23.4
Industry 28.7
Price to book
2.35
Peers 4.99
Dividend yield
0.49%
ROE
0.3%
Peers 14.7%
ROCE
2.5%
Peers 17.9%
Debt to equity
0.25
Debt ₹100 Cr
EPS (TTM)
₹4.33
Face value ₹1
OPM (TTM)
−12.6%
Net margin 12.1%
Sales growth
−10.9%
Latest quarter vs a year ago
Profit growth
n/a
Year-ago quarter not reported
Price to sales
2.84
EV/EBITDA −24.5

Strengths and risks

Risks to check

  • Return on equity is low at 0.3%.
  • Quarterly sales down 10.9% on a year ago.
  • Net profit is above operating profit, so a one-off gain is likely flattering earnings.
  • Interest coverage of only 0.0×.

No standout strengths in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Themis Medicare

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It provides active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and…

Headquarters
Mumbai
Employees
1,340
Sector
Healthcare
ISIN
INE083B01024
Website
themismedicare.com

Price range

52 weeks

₹64.95₹140.60

Today

₹99.48₹102.88
Avg volume (3M)
2.3 L
1-year return
minus 16.9%
From 52-week high
minus 28.0%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
THEMISMEDThemis Medicare101.25minus 0.38%94023.42.352.5%0.3%−12.6%−0.4%−72.8%0.49%minus 16.9%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
97.67890.176.587
10881.180.372.8139
−10.1−3.19.83.8−52.4
−10.3%−4.0%10.9%4.9%−60.3%
156.810.63.6
2.52.82.72.73
2.62.62.62.62.5
––−0.9–93
−14.1−3.510.49.138.6
−1.1%−4.8%2.8%1.9%36.2%
−14.2−3.610.18.924.6
-1.54-0.391.090.962.67

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
−0.4%
Profit CAGR 3Y
−72.8%
EPS CAGR 3Y
−73.1%
ROE
0.3%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
344377400340
–+9.3%+6.2%minus 15.1%
277325351339
67.551.549.10.4
19.6%13.7%12.3%0.1%
23.521.7921.6
87.68.58.9
10.512.29.910.3
0.10.1−0−0.8
72.553.439.71.9
21.5%18.6%24.8%40.7%
56.943.529.81.1
–minus 23.5%minus 31.5%minus 96.2%
6.174.723.240.12

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
9.29.29.29.2
330368393389
92.495.883100
82.19310299.2
514566588598
164170175169
2.62.62.52.5
0.71.31.51.5
12.59.96.64.5
334382403420
514566588598

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
16.122.134.7−3.3
−24−15.9−12.2−2.5
0.1−8.8−25.93.8
−7.7−2.6−3.4−2
−28.7−18.4−15.4−4.9
−12.73.719.3−8.1
−4.6−4.6−4.6−4.6

Shareholding pattern

Source: NSE filings
67.1%
promoters
  • Promoters67.11%
  • Public32.89%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202667.11%32.89%0.00
30 Jun 202667.11%32.89%0.00
31 Mar 202667.11%32.89%0.00
31 Dec 202567.11%32.89%minus 0.04
30 Sep 202567.15%32.85%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you